Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385653502> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- W4385653502 endingPage "1" @default.
- W4385653502 startingPage "1" @default.
- W4385653502 abstract "Background: Patients with non-muscle invasive bladder cancer (NMIBC) often have transurethral resection of the bladder tumor (TURBT). Inadequate TURBT, floating tumor cell implantation theory, and non-visualized microtumors are major factors for the recurrence of bladder cancer. According to guideline recommendations, after primary TURBT, there is a role of restage TURBT within 2–6 weeks in high-risk patients. The present study’s goal was to assess the role of restage TURBT in high-risk NMIBC. Aims and Objectives: The aim of the study was to identify the group of patients with high-risk NMIBC who may skip the commonly performed restage TURBT operation. Materials and Methods: In this prospective and observational study, biopsy-proven NMIBC patients with gross total painless hematuria secondary to urinary bladder mass from October 2017 to June 2019 were enrolled. Patients with high-risk disease will undergo restage TURBT after 2–6 weeks of primary TURBT. Residual/recurrent disease and tumor upstaging were recorded. To investigate the risk variables for tumor upstaging after restaging TURBT and residual/recurrent disease, logistic regression analysis was utilized. Results: A total of 250 patients (deep muscle involvement, n = 237 and no muscle involvement, n = 13) with histopathologic ally-confirmed high-risk disease following re-TURBT were included in the final analysis. During re-TURBT, 18% of patients had residual or recurrent tumors. The presence of upper tract changes, presence of perivesical fat stranding and tumor size >3 cm, high-grade histopathology, and positive urine for malignant cytology had a higher risk of residual or recurrent disease. Histopathological specimens showing the absence of muscle in the primary TURBT specimen, the presence of recurrent/residual growth in restage TURBT specimen, and bladder tumor antigen increased the risk of upstaging. Conclusion: Despite the low recurrence rate of tumors in restage TURBT, restage TURBT within 2–6 weeks of primary TURBT is an essential step for the accurate diagnosis among NMIBC patients. This further aids in deciding the subsequent treatment step in patients having upstaging and recurrent/residual tumors." @default.
- W4385653502 created "2023-08-09" @default.
- W4385653502 creator A5010724703 @default.
- W4385653502 creator A5017520591 @default.
- W4385653502 creator A5022734062 @default.
- W4385653502 creator A5031982353 @default.
- W4385653502 creator A5049510711 @default.
- W4385653502 creator A5069771081 @default.
- W4385653502 date "2023-01-01" @default.
- W4385653502 modified "2023-09-24" @default.
- W4385653502 title "Role of restage transurethral resection of bladder tumor in high-risk non-muscle invasive bladder cancer" @default.
- W4385653502 doi "https://doi.org/10.5455/njppp.2023.13.07363202327072023" @default.
- W4385653502 hasPublicationYear "2023" @default.
- W4385653502 type Work @default.
- W4385653502 citedByCount "0" @default.
- W4385653502 crossrefType "journal-article" @default.
- W4385653502 hasAuthorship W4385653502A5010724703 @default.
- W4385653502 hasAuthorship W4385653502A5017520591 @default.
- W4385653502 hasAuthorship W4385653502A5022734062 @default.
- W4385653502 hasAuthorship W4385653502A5031982353 @default.
- W4385653502 hasAuthorship W4385653502A5049510711 @default.
- W4385653502 hasAuthorship W4385653502A5069771081 @default.
- W4385653502 hasConcept C121608353 @default.
- W4385653502 hasConcept C126322002 @default.
- W4385653502 hasConcept C126838900 @default.
- W4385653502 hasConcept C126894567 @default.
- W4385653502 hasConcept C141071460 @default.
- W4385653502 hasConcept C151956035 @default.
- W4385653502 hasConcept C188816634 @default.
- W4385653502 hasConcept C2780352672 @default.
- W4385653502 hasConcept C2992225637 @default.
- W4385653502 hasConcept C71924100 @default.
- W4385653502 hasConceptScore W4385653502C121608353 @default.
- W4385653502 hasConceptScore W4385653502C126322002 @default.
- W4385653502 hasConceptScore W4385653502C126838900 @default.
- W4385653502 hasConceptScore W4385653502C126894567 @default.
- W4385653502 hasConceptScore W4385653502C141071460 @default.
- W4385653502 hasConceptScore W4385653502C151956035 @default.
- W4385653502 hasConceptScore W4385653502C188816634 @default.
- W4385653502 hasConceptScore W4385653502C2780352672 @default.
- W4385653502 hasConceptScore W4385653502C2992225637 @default.
- W4385653502 hasConceptScore W4385653502C71924100 @default.
- W4385653502 hasIssue "0" @default.
- W4385653502 hasLocation W43856535021 @default.
- W4385653502 hasOpenAccess W4385653502 @default.
- W4385653502 hasPrimaryLocation W43856535021 @default.
- W4385653502 hasRelatedWork W2365022899 @default.
- W4385653502 hasRelatedWork W2370208313 @default.
- W4385653502 hasRelatedWork W2384311157 @default.
- W4385653502 hasRelatedWork W2395732460 @default.
- W4385653502 hasRelatedWork W2480000808 @default.
- W4385653502 hasRelatedWork W2771908915 @default.
- W4385653502 hasRelatedWork W324577642 @default.
- W4385653502 hasRelatedWork W4205910527 @default.
- W4385653502 hasRelatedWork W2118673085 @default.
- W4385653502 hasRelatedWork W2610028178 @default.
- W4385653502 isParatext "false" @default.
- W4385653502 isRetracted "false" @default.
- W4385653502 workType "article" @default.